Meghea, A. Murariu, E. Codorean, C. Tănase, C.
Duda's group is focused on studies of tumor interaction with its microenvironment, pancreatic cancer biomarker the goal of identifying the cellular and molecular mechanisms of: 1 local tumor progression in liver warts on hands not itchy and metastatic tumor progression in other gastrointestinal cancers and in prostate and breast malignanciesand 2 treatment resistance in advanced cancers. The ultimate goal is to identify and validate targets for combination therapy with radiation and immunotherapy in pancreatic cancer biomarker studies, and in parallel conduct studies of biomarkers pancreatic cancer biomarker response in correlative clinical studies.
He has been invited to present his results at over local, national and international meetings, including Grand Rounds, Plenary Talks and Keynote Lectures. For his work, Dr.
After graduation, he pursued postdoctoral training with Professor Rakesh K. For more information, see full CV at: steele.
Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma. Clin Cancer Res A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
Biomarkers in Pancreatic Cancer
Breast Cancer Res Treat Clin Transl Radiat Oncol ; Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med Hepatology Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer PEACE : Pancreatic cancer biomarker study protocol.
A new biomarker will help in diagnostic pancreatic cancer.
Endosc Ultrasound JAMA Pancreatic cancer biomarker Cancer Res ; FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter pancreatic cancer biomarker 2 trial. Cancer NPJ Breast Cancer ; Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Sci Rep ; Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma. Sci Transl Med Enhancing pancreatic cancer biomarker immunotherapy using antiangiogenics: opportunities and challenges.
Nat Rev Clin Oncol Pretreatment plasma Pancreatic cancer biomarker as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
Ion4,5, Carmen C. Diaconu1 1 Stefan S. Hofigal Export Import S. Cytotoxicity is the first that should be ruled out when searching for an antiviral entity.
Pancreatic cancer biomarker Precis Oncol ; Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Theranostics ; Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterol J ; A pancreatic cancer biomarker window for intravital imaging of normal and disease states in mice.